Cargando…
aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1
Gallbladder cancer (GBC) is a highly malignant bile duct cancer with poor prognosis characterized by its insensitivity to chemotherapy. Emerging evidence indicates that cytoprotective antioxidation is involved in drug resistance of various cancers; however, the underlying molecular mechanisms remain...
Autores principales: | Tian, Li, Lu, Yun, Yang, Tao, Deng, Zhengdong, Xu, Lei, Yao, Wei, Ma, Chaoqun, Li, Xiangyu, Zhang, Jian, Liu, Yan, Wang, Jianming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6395946/ https://www.ncbi.nlm.nih.gov/pubmed/30822690 http://dx.doi.org/10.1016/j.redox.2019.101149 |
Ejemplares similares
-
Downregulation of ASPP2 promotes gallbladder cancer metastasis and macrophage recruitment via aPKC-ι/GLI1 pathway
por: Tian, Li, et al.
Publicado: (2018) -
Transcription co-activator P300 activates Elk1-aPKC-ι signaling mediated epithelial-to-mesenchymal transition and malignancy in hepatocellular carcinoma
por: Ma, Chaoqun, et al.
Publicado: (2020) -
The aPKCι blocking agent ATM negatively regulates EMT and invasion of hepatocellular carcinoma
por: Ma, C Q, et al.
Publicado: (2014) -
Lack of an association between the aPKCλ/ι expression in prostate cancer and the patient outcomes
por: Yokomizo, Yumiko, et al.
Publicado: (2017) -
The Rho family GEF FARP2 is activated by aPKCι to control tight junction formation and polarity
por: Elbediwy, Ahmed, et al.
Publicado: (2019)